2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

2:30PM-4:00PM: Abstract Number: 3084

Progression of Lupus Pathology Is Correlative with Cardiac Magnetic Resonance Imaging Abnormalities, Diminished Function, and Inflammatory Histopathology in an Animal Model

2015 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3101

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Sclerostin Are Related to Joint Destruction in Early Rheumatoid Arthritis Unrelated to Polymorphisms of the Genes

Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

2:30PM-4:00PM: Abstract Number: 3106

Regulation of ASK1 Expression By microRNA-17 and Their Correlation with Rheumatoid Arthritis Pathogenesis

Rheumatoid Arthritis - Human Etiology and Pathogenesis III

2:30PM-4:00PM: Abstract Number: 3134

Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 3137

Scleroderma Hand Contracture Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 3139

Screening Algorithm for Pulmonary Hypertension in Systemic Sclerosis – Comparison of Predictive Accuracy of Three Algorithms

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics II

2:30PM-4:00PM: Abstract Number: 3127

Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®

Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Neuropsychiatric Lupus

2:30PM-4:00PM: Abstract Number: 3108

Serum 14-3-3eta Are Elevated in Indigenous North Americans with Rheumatoid Arthritis and May Predict Imminent Synovitis in Their at-Risk First Degree Relatives

Rheumatoid Arthritis - Human Etiology and Pathogenesis III

2:30PM-4:00PM: Abstract Number: 3109

Single Cell Gene Expression in Classical Monocytes Correlates with Treatment Response Groups to TNF-Alpha Inhibition in Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis III

2:30PM-4:00PM: Abstract Number: 3098

Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease at 12 Months: Results from the Pathobiology of Early Arthritis Cohort

Rheumatoid Arthritis - Clinical Aspects IV: Biomarkers, Disease Progression and Treatment Response

2:30PM-4:00PM: Abstract Number: 3133

The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated By the Urokinase Pathway Via Binding to Enolase-1 and Urokinase Plasminogen Activator Receptor

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

2:30PM-4:00PM: Abstract Number: 3120

The Prevalence, Incidence and Management of Hypertension, Diabetes and Hyperlipidemia in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis - CoMorbidities

2:30PM-4:00PM: Abstract Number: 3105

The RA Immune System Recreated in Immunodeficient Mice By Thymic Differentiation from RA Patients’ Hematopoietic Stem Cells Exhibits Marked CD4 T Cell Activation and Differentiation

Rheumatoid Arthritis - Human Etiology and Pathogenesis III

2:30PM-4:00PM: Abstract Number: 3119

The Risk of Venous Thromboembolism in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis - CoMorbidities

2:30PM-4:00PM: Abstract Number: 3086

The Same Multidimensional Patient Health Assessment Questionnaire Used to Assess RAPID3 in Rheumatoid Arthritis, Osteoarthritis and Other Rheumatic Diseases Can Provide Quantitative Clues to Recognize and Document Comorbid Fibromyalgia

Fibromyalgia: Clinical Issues

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].